Phase 2 Breast Clinical Trials
699 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 699 trials
Recruiting
Phase 2
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Advanced Breast Cancer
AstraZeneca24 enrolled6 locationsNCT07427394
Recruiting
Phase 2
A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
Advanced Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.36 enrolled1 locationNCT07597629
Recruiting
Phase 2
Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors
Estrogen Receptor-Positive Breast Carcinoma
Mayo Clinic80 enrolled23 locationsNCT06028022
Recruiting
Phase 2
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
Breast Carcinoma
Mayo Clinic60 enrolled5 locationsNCT05557877
Recruiting
Phase 2
Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of TNBC-BM.
TNBC - Triple-Negative Breast CancerBrain Metastasases
Fudan University58 enrolled1 locationNCT07638852
Recruiting
Phase 2
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Breast Cancer
Hoffmann-La Roche80 enrolled45 locationsNCT07405801
Recruiting
Phase 1Phase 2
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Breast CancerPancreatic CancerOvarian Cancer+2 more
National Cancer Institute (NCI)124 enrolled1 locationNCT02830724
Recruiting
Phase 1Phase 2
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Breast Cancer
Genentech, Inc.285 enrolled45 locationsNCT07100106
Recruiting
Phase 2
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaInvasive Breast Carcinoma
National Cancer Institute (NCI)70 enrolled30 locationsNCT03606967
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Metastatic Breast CarcinomaMetastatic Ovarian CancerMetastatic Pancreatic Cancer+2 more
National Cancer Institute (NCI)332 enrolled1 locationNCT01174121
Recruiting
Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Breast CancerMetastatic Breast CancerBreast Neoplasms+6 more
Kristina A. Fanucci297 enrolled1 locationNCT07222215
Recruiting
Phase 1Phase 2
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Triple-Negative Breast CancerMelanomaNon-small Cell Lung Cancer+6 more
AstraZeneca60 enrolled13 locationsNCT07115043
Recruiting
Phase 1Phase 2
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.80 enrolled1 locationNCT06974929
Recruiting
Phase 2
Capecitabine in ER+/HER2-negative Breast Cancer
Breast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage III+1 more
University Health Network, Toronto15 enrolled1 locationNCT07631052
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled295 locationsNCT06926868
Recruiting
Phase 2
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8+26 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04771520
Recruiting
Phase 2
18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer
Breast Cancer FemaleLobular Breast CarcinomaPET/MRI+2 more
Università Vita-Salute San Raffaele119 enrolled1 locationNCT05982496
Recruiting
Phase 2
Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study
Breast Cancer
Fudan University53 enrolled1 locationNCT07647016
Recruiting
Phase 2
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
Breast CancerDCISLCIS
University of Wisconsin, Madison30 enrolled1 locationNCT03936478